Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Halozyme Therapeutics stock price, quote, forecast and news

HALO
US40637H1095
A0DLHS

Price

62.72
Today +/-
+0.96
Today %
+1.74 %
P

Halozyme Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Halozyme Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Halozyme Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Halozyme Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Halozyme Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Halozyme Therapeutics Stock Price History

DateHalozyme Therapeutics Price
8/23/202462.72 undefined
8/22/202461.64 undefined
8/21/202462.17 undefined
8/20/202460.93 undefined
8/19/202461.74 undefined
8/16/202459.42 undefined
8/15/202459.10 undefined
8/14/202457.41 undefined
8/13/202455.99 undefined
8/12/202456.07 undefined
8/9/202455.20 undefined
8/8/202454.46 undefined
8/7/202454.12 undefined
8/6/202451.94 undefined
8/5/202452.11 undefined
8/2/202454.09 undefined
8/1/202455.05 undefined
7/31/202455.26 undefined
7/30/202455.69 undefined
7/29/202455.47 undefined

Halozyme Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Halozyme Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Halozyme Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Halozyme Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Halozyme Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Halozyme Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Halozyme Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Halozyme Therapeutics’s growth potential.

Halozyme Therapeutics Revenue, EBIT and net profit per share

DateHalozyme Therapeutics RevenueHalozyme Therapeutics EBITHalozyme Therapeutics Net Income
2029e1.74 B undefined0 undefined1.11 B undefined
2028e1.78 B undefined1.18 B undefined1.1 B undefined
2027e1.67 B undefined1.08 B undefined1.02 B undefined
2026e1.42 B undefined856.74 M undefined814.63 M undefined
2025e1.17 B undefined659.66 M undefined621.96 M undefined
2024e1 B undefined518.31 M undefined514.41 M undefined
2023829.25 M undefined340.07 M undefined281.59 M undefined
2022660.1 M undefined289.4 M undefined202.1 M undefined
2021443.3 M undefined275.9 M undefined402.7 M undefined
2020267.6 M undefined144.3 M undefined129.1 M undefined
2019196 M undefined-67.6 M undefined-72.2 M undefined
2018151.9 M undefined-69.3 M undefined-80.3 M undefined
2017316.6 M undefined81 M undefined63 M undefined
2016146.7 M undefined-83.2 M undefined-103 M undefined
2015135.1 M undefined-27.5 M undefined-32.2 M undefined
201475.3 M undefined-63 M undefined-68.4 M undefined
201354.8 M undefined-80.4 M undefined-83.5 M undefined
201242.3 M undefined-53.6 M undefined-53.6 M undefined
201156.1 M undefined-18.5 M undefined-19.8 M undefined
201013.6 M undefined-53 M undefined-53.2 M undefined
200913.7 M undefined-58.5 M undefined-58.4 M undefined
20088.8 M undefined-50.4 M undefined-48.7 M undefined
20073.8 M undefined-28.1 M undefined-23.9 M undefined
20061 M undefined-15.6 M undefined-14.8 M undefined
2005100,000 undefined-13.6 M undefined-13.3 M undefined
20040 undefined-9.1 M undefined-9.1 M undefined

Halozyme Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000.010.010.010.060.040.050.080.140.150.320.150.20.270.440.660.8311.171.421.671.781.74
-----200.00166.6762.50-330.77-25.0028.5738.8980.008.15116.44-52.2229.8036.2265.9248.9825.6121.1116.2422.0217.286.35-2.03
-----100.00100.00100.0092.3198.2197.6288.8969.3377.7877.4090.1993.3876.5383.9081.4978.7976.72------
0000038131255414852105113285141150224361520636000000
-0-0-0.01-0.01-0.02-0.03-0.05-0.06-0.05-0.02-0.05-0.08-0.06-0.03-0.080.08-0.07-0.070.140.280.290.340.520.660.861.081.180
-----1,500.00-933.33-625.00-446.15-407.69-32.14-126.19-148.15-84.00-20.00-56.8525.63-45.70-34.1853.9362.0843.7941.0151.5956.4760.1164.5566.44-
-0-0-0.01-0.01-0.01-0.02-0.05-0.06-0.05-0.02-0.05-0.08-0.07-0.03-0.10.06-0.08-0.070.130.40.20.280.510.620.811.021.11.11
-100.00350.0044.447.6964.29108.7020.83-8.62-64.15178.9556.60-18.07-52.94221.88-161.17-226.98-10.00-279.17211.63-49.7539.1182.9220.8231.0824.948.160.91
4.66.835.450.362.674.379.886.794.4102.6111.1112.8122.7126.7128139.1143.6144.3141.5146.8140.6134.2000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Halozyme Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Halozyme Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.10.51619.144.297.763.767.583.352.899.571.5135.6108.3205469.2354.5421.3368740.9362.8336
0000.40.40.87.34.22.32.315.79.19.132.415.722.13059.497.791231.1234.21
0000000000000000000000
000.10.30.40.70.41.20.20.62.76.26.49.514.65.122.629.460.753.9100.1127.6
000.10.30.622.61.63.78.312.88.410.121.521.213.920.733.428.340.54548.61
0.10.516.220.145.6101.27474.589.564130.795.2161.2171.7256.5510.3427.8543.5554.7926.3739746.42
0.10.10.20.40.52.32.62.71.81.83.73.433.94.33.57.510.910.68.875.674.94
0000000000000000000000
0000000000000000000000
00000000000000000000546.7472.88
00000000000000000000409416.82
00000000000.43.21.76.10.76.14.911.614.6169.371.222.2
000000000000.0100.010.010.010.010.020.030.181.10.99
000.020.020.050.10.080.080.090.070.130.10.170.180.260.520.440.570.581.11.841.73
1.54.400.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.13
0027.844.564.1122.7128.9178.8245.5255.8347.3361.9491.7525.6552.7731780.5695.1625.5256.327.42.41
-1.9-4-13.1-26.3-41.1-65-113.7-172-225.3-245-298.6-382.1-450.4-482.7-585.3-522.4-531.4-603.7-474.6-58.9143.290.55
0000000000000-1000-500-3002000-600-900-9,278
0000000000000000000000
-0.40.414.718.323.157.815.36.920.310.948.8-20.141.442.9-32.5208.2248.991.7151196.9169.883.81
0.10.21.51.423.16.72.83.87.62.33.134.53.67.94.16.41.91.517.711.82
0.10.10.10.712.546.18.65.67.814.41426.828.839.649.555.620.524.496.599.72
0000.31.23.33.65.52.94.18.97.47.49.34.86.64.241.71.73.20.96
400000000000000000000000
000000000000021.917.477.291.519.5397.289.413.30
0.60.31.62.44.28.914.314.415.317.31924.924.462.554.6131.3149.385.5421.3117130.7112.49
00000000000.030.050.050.030.20.130.030.3800.791.491.5
0000000000000000000000
000018.836.84755.855.737.635.847.150.448.440.255.17.15.47.53.148.237.72
00000.020.040.050.060.060.040.070.10.10.080.240.180.040.390.010.791.541.54
00000.020.050.060.070.070.050.090.120.120.140.290.310.190.470.430.911.671.65
000.020.020.050.10.080.080.090.070.130.10.170.180.260.520.440.570.581.11.841.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Halozyme Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Halozyme Therapeutics's financial health and stability.

Assets

Halozyme Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Halozyme Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Halozyme Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Halozyme Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-2-9-13-14-23-48-58-53-19-53-83-68-32-10363-80-72129402202281
000000111111112224334984
0000000000000000000-1554034
001020208121-21-20220-291743-2-50-1033-86-38
00001279911162034435856676844665862
0000000000033332016963611
000000000000001300001631
0-1-7-1370-35-40-45-34-64-49-47-37-50134-49-8555299240388
00000-2-1-100-1-2-1-2-3-1-4-4-2-1-4-15
00000-2-1-100-1-47-335-76-1632-578-406-487-96
00000000000-45-318-73-1627-180-404-482-81
0000000000000000000000
0000000000292000148-16-77339-19415624-13
001516185624561483511413114713-185-86-337-186-394
01231618562456141122511413150131-63153-10677362-407
01700000000000000000-760
0000000000000000000000
001532553-34315-3047-7234-1823102-1106227-29115-116
-1.1-1.6-7.9-13.46.7-2.5-36.6-41.6-46-35.1-65.7-51.6-48.9-39.5-53.5132.7-54.2-89.453297.9235.3373.28
0000000000000000000000

Halozyme Therapeutics stock margins

The Halozyme Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Halozyme Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Halozyme Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Halozyme Therapeutics's sales revenue. A higher gross margin percentage indicates that the Halozyme Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Halozyme Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Halozyme Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Halozyme Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Halozyme Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Halozyme Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Halozyme Therapeutics Margin History

Halozyme Therapeutics Gross marginHalozyme Therapeutics Profit marginHalozyme Therapeutics EBIT marginHalozyme Therapeutics Profit margin
2029e76.8 %0 %63.8 %
2028e76.8 %66.44 %61.95 %
2027e76.8 %64.55 %60.94 %
2026e76.8 %60.16 %57.21 %
2025e76.8 %56.53 %53.3 %
2024e76.8 %51.62 %51.24 %
202376.8 %41.01 %33.96 %
202278.9 %43.84 %30.62 %
202181.64 %62.24 %90.84 %
202083.78 %53.92 %48.24 %
201976.73 %-34.49 %-36.84 %
201893.29 %-45.62 %-52.86 %
201790.18 %25.58 %19.9 %
201677.37 %-56.71 %-70.21 %
201578.31 %-20.36 %-23.83 %
201469.85 %-83.67 %-90.84 %
201388.69 %-146.72 %-152.37 %
201297.4 %-126.71 %-126.71 %
201199.47 %-32.98 %-35.29 %
201092.65 %-389.71 %-391.18 %
200997.81 %-427.01 %-426.28 %
200895.45 %-572.73 %-553.41 %
200794.74 %-739.47 %-628.95 %
200650 %-1,560 %-1,480 %
2005100 %-13,600 %-13,300 %
200476.8 %0 %0 %

Halozyme Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Halozyme Therapeutics earnings per share therefore indicates how much revenue Halozyme Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Halozyme Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Halozyme Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Halozyme Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Halozyme Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Halozyme Therapeutics Revenue, EBIT and net profit per share

DateHalozyme Therapeutics Sales per ShareHalozyme Therapeutics EBIT per shareHalozyme Therapeutics Earnings per Share
2029e13.68 undefined0 undefined8.73 undefined
2028e13.95 undefined0 undefined8.64 undefined
2027e13.12 undefined0 undefined8 undefined
2026e11.19 undefined0 undefined6.4 undefined
2025e9.17 undefined0 undefined4.89 undefined
2024e7.89 undefined0 undefined4.04 undefined
20236.18 undefined2.53 undefined2.1 undefined
20224.69 undefined2.06 undefined1.44 undefined
20213.02 undefined1.88 undefined2.74 undefined
20201.89 undefined1.02 undefined0.91 undefined
20191.36 undefined-0.47 undefined-0.5 undefined
20181.06 undefined-0.48 undefined-0.56 undefined
20172.28 undefined0.58 undefined0.45 undefined
20161.15 undefined-0.65 undefined-0.8 undefined
20151.07 undefined-0.22 undefined-0.25 undefined
20140.61 undefined-0.51 undefined-0.56 undefined
20130.49 undefined-0.71 undefined-0.74 undefined
20120.38 undefined-0.48 undefined-0.48 undefined
20110.55 undefined-0.18 undefined-0.19 undefined
20100.14 undefined-0.56 undefined-0.56 undefined
20090.16 undefined-0.67 undefined-0.67 undefined
20080.11 undefined-0.63 undefined-0.61 undefined
20070.05 undefined-0.38 undefined-0.32 undefined
20060.02 undefined-0.25 undefined-0.24 undefined
20050 undefined-0.27 undefined-0.26 undefined
20040 undefined-0.26 undefined-0.26 undefined

Halozyme Therapeutics business model

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics is one of the most popular companies on Eulerpool.com.

Halozyme Therapeutics SWOT Analysis

Strengths

Halozyme Therapeutics Inc has a robust and diverse product portfolio that includes a range of innovative and effective therapies. This allows the company to cater to various medical conditions and target a wide market segment.

The company has a proven track record of developing and commercializing successful therapies. This track record enhances its reputation and credibility in the market, attracting investors and potential strategic partners.

Weaknesses

Halozyme Therapeutics Inc heavily relies on partnerships with other pharmaceutical companies for research, development, and commercialization. This dependency exposes the company to risks associated with potential conflicts, delays, or failures in partnerships.

The pharmaceutical industry is subject to strict regulatory guidelines and approvals. Halozyme Therapeutics Inc may face challenges in obtaining regulatory clearances for its therapies, which can lead to delays in product launches and revenue generation.

Opportunities

The increasing prevalence of chronic diseases and the aging population create a growing demand for advanced therapies. Halozyme Therapeutics Inc can leverage this opportunity by developing and offering solutions that address unmet medical needs.

The company can explore expansion into new geographic markets to tap into additional revenue streams. By targeting emerging markets or regions with limited competition, Halozyme Therapeutics Inc can gain a competitive advantage and strengthen its market position.

Threats

The pharmaceutical industry is highly competitive, with numerous players vying for market share. Halozyme Therapeutics Inc faces the threat of competition from both established pharmaceutical companies and emerging biotech startups.

Protecting intellectual property rights is crucial in the pharmaceutical industry. Halozyme Therapeutics Inc may face risks such as patent infringements or unauthorized use of its technologies, potentially impacting its market exclusivity and revenue.

Halozyme Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Halozyme Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Halozyme Therapeutics shares outstanding

The number of shares was Halozyme Therapeutics in 2023 — This indicates how many shares 134.197 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Halozyme Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Halozyme Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Halozyme Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Halozyme Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Halozyme Therapeutics Stock splits

In Halozyme Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Halozyme Therapeutics.

Halozyme Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.77 0.91  (17.68 %)2024 Q2
3/31/20240.71 0.79  (11.44 %)2024 Q1
12/31/20230.84 0.82  (-2.56 %)2023 Q4
9/30/20230.72 0.75  (3.96 %)2023 Q3
6/30/20230.64 0.74  (15.3 %)2023 Q2
3/31/20230.49 0.47  (-3.39 %)2023 Q1
12/31/20220.48 0.48  (1.03 %)2022 Q4
9/30/20220.52 0.74  (41.36 %)2022 Q3
6/30/20220.51 0.53  (3.58 %)2022 Q2
3/31/20220.5 0.47  (-5.96 %)2022 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Halozyme Therapeutics stock

Eulerpool World ESG Rating (EESG©)

89/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees43.8
Percentage of women in management—
Percentage of Asian employees14.6
Share of Asian management—
Percentage of Hispanic/Latino employees9.5
Hispano/Latino Management share—
Percentage of Black employees4.4
Black Management Share—
Percentage of white employees69.5
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Halozyme Therapeutics list of shareholders

%
Name
Stocks
Change
Date
5.26 % Artisan Partners Limited Partnership6,689,058-1,023,81612/31/2023
5.09 % State Street Global Advisors (US)6,475,549266,01812/31/2023
2.91 % Snyder Capital Management, L.P.3,709,599-614,63312/31/2023
2.72 % AllianceBernstein L.P.3,463,694106,91812/31/2023
2.58 % Macquarie Investment Management3,282,640-161,55012/31/2023
2.29 % Geode Capital Management, L.L.C.2,919,763132,41412/31/2023
12.26 % BlackRock Institutional Trust Company, N.A.15,607,942645,96112/31/2023
10.40 % The Vanguard Group, Inc.13,232,275152,87012/31/2023
1.75 % GW&K Investment Management, LLC2,226,538-117,76712/31/2023
1.56 % TD Asset Management Inc.1,983,9161,662,39012/31/2023
1
2
3
4
5
...
10

Halozyme Therapeutics Executives and Management Board

Dr. Helen Torley60
Halozyme Therapeutics President, Chief Executive Officer, Director (since 2014)
Compensation 9.7 M
Mr. Mark Snyder56
Halozyme Therapeutics Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Compensation 3.74 M
Dr. Michael Labarre59
Halozyme Therapeutics Senior Vice President, Chief Technical Officer (since 2020)
Compensation 3.12 M
Ms. Nicole Labrosse40
Halozyme Therapeutics Chief Financial Officer, Senior Vice President
Compensation 2.68 M
Mr. Jeffrey Henderson58
Halozyme Therapeutics Independent Chairman of the Board
Compensation 382,719
1
2
3

Halozyme Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Inc. Stock
Thermo Fisher Scientific Inc.
SupplierCustomer0,920,690,24-0,04-0,430,20
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,780,510,860,770,25-0,23
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,74-0,100,730,560,65-0,02
argenx Stock
argenx
SupplierCustomer0,650,550,860,830,500,54
Catalent, Inc. Stock
Catalent, Inc.
SupplierCustomer0,650,44-0,08-0,110,070,52
Roche Holding AG Stock
Roche Holding AG
SupplierCustomer0,62-0,26-0,02-0,07-0,12-
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,530,340,820,69-0,15-0,37
Eli Lilly and Company Stock
Eli Lilly and Company
SupplierCustomer0,530,680,750,870,120,33
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,440,420,870,690,400,34
argenx SE Stock
argenx SE
SupplierCustomer0,30-0,06----
1
2
3

Most common questions regarding Halozyme Therapeutics

What values and corporate philosophy does Halozyme Therapeutics represent?

Halozyme Therapeutics Inc is a biotechnology company that is focused on developing and commercializing innovative cancer treatments. The company's values revolve around the commitment to improving patient outcomes and transforming the way cancer is treated. Halozyme aims to provide innovative therapies that are more effective, less invasive, and more accessible to patients worldwide. Their corporate philosophy is rooted in collaboration, continuous innovation, and patient-centricity. By working together with physicians, researchers, and partners, Halozyme strives to create novel solutions that address unmet medical needs and make a positive impact on the lives of cancer patients.

In which countries and regions is Halozyme Therapeutics primarily present?

Halozyme Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Halozyme Therapeutics achieved?

Halozyme Therapeutics Inc has achieved significant milestones throughout its history. Some of the notable achievements include the FDA approval of its Enhanze® drug delivery technology platform, which enables the subcutaneous administration of therapies that were previously only available intravenously. This innovative technology has been licensed to various renowned pharmaceutical companies, leading to successful collaborations and clinical advancements. Additionally, Halozyme has successfully developed and commercialized multiple products, such as Herceptin® SC and Hylenex®, providing patients with improved treatment options. With its continuous focus on research and development, Halozyme Therapeutics Inc remains committed to driving innovation in the field of drug delivery and enhancing patients' lives.

What is the history and background of the company Halozyme Therapeutics?

Halozyme Therapeutics Inc. is a biotechnology company founded in 1998. Based in San Diego, California, the company develops and commercializes innovative drug therapies for various diseases. Halozyme specializes in enzyme-based technologies that enable the subcutaneous delivery of injectable drugs. Their proprietary platform, Enhanze®, enables the dispersion and absorption of drugs that are typically administered intravenously. Through partnerships and collaborations with pharmaceutical and biotech companies, Halozyme has advanced the development of several therapeutic products. With a focus on enhancing treatment options, Halozyme Therapeutics Inc. continues to make significant contributions to the field of biotechnology.

Who are the main competitors of Halozyme Therapeutics in the market?

The main competitors of Halozyme Therapeutics Inc in the market are Bristol-Myers Squibb, Roche Holdings AG, and Johnson & Johnson.

In which industries is Halozyme Therapeutics primarily active?

Halozyme Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Halozyme Therapeutics?

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative treatments for patients with cancer, immune disorders, and other serious diseases. The company's business model revolves around its proprietary ENHANZE® drug delivery technology platform, which enables the subcutaneous administration of biologics by targeting the body's extracellular matrix. This approach offers numerous benefits, including reduced treatment times and improved convenience for patients, as well as potential cost savings for healthcare systems. Halozyme partners with leading pharmaceutical companies to apply its technology to a wide range of therapeutic areas, aiming to improve treatment options and ultimately enhance patients' lives.

What is the P/E ratio of Halozyme Therapeutics 2024?

The Halozyme Therapeutics P/E ratio is 16.36.

What is the P/S ratio of Halozyme Therapeutics 2024?

The Halozyme Therapeutics P/S ratio is 8.38.

What is the AlleAktien quality score of Halozyme Therapeutics?

The AlleAktien quality score for Halozyme Therapeutics is 6/10.

What is the revenue of Halozyme Therapeutics 2024?

The expected Halozyme Therapeutics revenue is 1 B USD.

How high is the profit of Halozyme Therapeutics 2024?

The expected Halozyme Therapeutics profit is 514.41 M USD.

What is the business model of Halozyme Therapeutics

Halozyme Therapeutics Inc is a biopharmaceutical company based in San Diego, California. The company specializes in the development and commercialization of enzyme technology platforms used in the treatment of cancer and other serious diseases. Their main business model is focused on improving pharmaceutical drug delivery through the development and marketing of enzyme technology platforms. These technology platforms enable the administration of therapeutic proteins and other drugs at higher concentrations and for longer periods of time. Halozyme offers several products based on their technology platforms, including PEGPH20, an enzyme used in the treatment of pancreatic cancer. PEGPH20 helps shrink tumors and increase tumor blood flow to allow for more effective treatment. Halozyme Therapeutics also provides enzymes like hyaluronidase, which help break through the blood-brain barrier, allowing for better absorption of medications and other drugs into the brain. This can be of great advantage in treating neurological diseases such as Alzheimer's and Parkinson's. Another product from Halozyme is their Enhanze enzyme technology platform, which enables the administration of therapeutic proteins at higher concentrations and for longer periods of time. This technology has the potential to improve the treatment of chronic diseases like arthritis and blood disorders. Additionally, Halozyme Therapeutics collaborates closely with other pharmaceutical companies to integrate their technology platforms into their product development. This allows the company to benefit from licensing revenues and milestone payments resulting from these partnerships. Another business model of Halozyme Therapeutics is the development of biosimilars. Biosimilars are replicas of biopharmaceutical drugs that are already available on the market. These drugs are typically more cost-effective than the original products and can help improve access to life-saving medications. Halozyme Therapeutics has partnered with a major pharmaceutical company to develop biosimilars for several drugs. The company's enzyme technology platforms enable the improvement of efficacy and safety of these biosimilars, which can contribute to faster regulatory approval. Overall, Halozyme Therapeutics has developed a diverse business model based on the development and commercialization of enzyme technology platforms. Through collaboration with other pharmaceutical companies, the company can increase its market share and expand the application of its technology platforms to new areas.

What is the Halozyme Therapeutics dividend?

Halozyme Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Halozyme Therapeutics pay dividends?

The dividend cannot currently be calculated for Halozyme Therapeutics or the company does not pay out a dividend.

What is the Halozyme Therapeutics ISIN?

The ISIN of Halozyme Therapeutics is US40637H1095.

What is the Halozyme Therapeutics WKN?

The WKN of Halozyme Therapeutics is A0DLHS.

What is the Halozyme Therapeutics ticker?

The ticker of Halozyme Therapeutics is HALO.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.

All fundamentals about Halozyme Therapeutics

Our stock analysis for Halozyme Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.